|
||||||||||||||||||||||
|
|
Phase III Randomized Comparison of Lobectomy vs Limited Pulmonary Resection for T1 N0 non-Small Cell Lung Carcinoma (Summary Last Modified 11/88)
Basic Trial Information
Objectives I. Determine whether limited pulmonary resection (segmental or wedge resection) affords the same potential for cure as standard lobectomy in patients with T1 N0 non-small cell carcinoma of the lung. II. Determine whether limited resection is comparable to lobectomy with reference to in-hospital mortality and morbidity. III. Determine whether limited pulmonary resection maintains better pulmonary function and reserve than lobectomy. Entry Criteria Disease Characteristics: See General Eligibility Criteria Patient Characteristics: See General Eligibility Criteria General Eligibility Criteria: Patients of any age with presumed non-small cell carcinoma of the lung in whom the segmental bronchial orifice contains no carcinoma at bronchoscopy. The surgical stage must be T1 N0 M0 and the tumor must be amenable to complete surgical removal. There may be no segmental lymph nodes involved with tumor. There may be no history of renal cell carcinoma, melanoma, breast cancer, or GI cancer. There may be no history of any other cancer, except nonmelanomatous skin cancer or in situ carcinoma of the cervix, unless there is a 5-year disease-free interval since last therapy. Expected Enrollment 215 eligible patients will be entered over 3.6 years. As of October, 1988, the accrual goal has been increased to 240 eligible patients; it is estimated that a total accrual of 275 patients will be required to achieve this goal. Outline Randomized study. Arm I: Surgery. Lobectomy. Arm II: Surgery. Limited Resection.Published Results Ginsberg RJ, Rubinstein LV: Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 60 (3): 615-22; discussion 622-3, 1995.[PUBMED Abstract] Ginsberg RJ, Rubinstein L: The comparison of limited resection to lobectomy for T1N0 non-small cell lung cancer. LCSG 821. Chest 106 (6 Suppl): 318S-319S, 1994.[PUBMED Abstract] Trial Lead Organizations Lung Cancer Study Group
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |